RHD genotyping for prenatal patients with a serologic weak D phenotype

Introduction: In 2014, the College of American Pathologists (CAP) Transfusion Medicine Resource Committee (TMRC) recommended genotyping of prenatal patients with a discordant and/or serologic weak D phenotype. Patients found to be weak D types 1, 2, or 3 are treated as D+, avoiding Rh immune globulin. This is already the policy for CBS prenatal programs in western Canada. In Ontario and Nova Scotia, samples are being sent to CBS from selected hospitals for D genotyping. We compared results from Ontario and Nova Scotia with those obtained in Alberta and anticipated by TMRC.
Source: Transfusion Medicine Reviews - Category: Hematology Authors: Source Type: research